Caroline Young bought $256 of CPIX
director at CUMBERLAND PHARMACEUTICALS INC. 154 shares at an average of $1.66, traded Dec 2, 2024, filed Dec 30, 2024.
Score components
- +15RoleDirector
- 0Trade size$256 at market
- -5Relative to holdingsUnder 1% of holdings (0.5%)
- 0Price contextNo price history yet
- +15Cluster4 insiders buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -1510b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-24-052610, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 2, 2024 | POpen-market purchase Common Stock10b5-1 | +15 | $1.33 | $20 | 29,679 | Dec 30, 2024 |
| Dec 3, 2024 | POpen-market purchase Common Stock10b5-1 | +15 | $1.26 | $19 | 29,694 | Dec 30, 2024 |
| Dec 4, 2024 | POpen-market purchase Common Stock10b5-1 | +15 | $1.22 | $18 | 29,709 | Dec 30, 2024 |
| Dec 5, 2024 | POpen-market purchase Common Stock10b5-1 | +15 | $1.20 | $18 | 29,724 | Dec 30, 2024 |
| Dec 6, 2024 | POpen-market purchase Common Stock10b5-1 | +15 | $1.20 | $18 | 29,739 | Dec 30, 2024 |
| Dec 9, 2024 | POpen-market purchase Common Stock10b5-1 | +15 | $1.25 | $19 | 29,754 | Dec 30, 2024 |
| Dec 10, 2024 | POpen-market purchase Common Stock10b5-1 | +7 | $2.48 | $17 | 29,761 | Dec 30, 2024 |
| Dec 11, 2024 | POpen-market purchase Common Stock10b5-1 | +7 | $2.29 | $16 | 29,768 | Dec 30, 2024 |
| Dec 12, 2024 | POpen-market purchase Common Stock10b5-1 | +7 | $2.19 | $15 | 29,775 | Dec 30, 2024 |
| Dec 13, 2024 | POpen-market purchase Common Stock10b5-1 | +7 | $2.33 | $16 | 29,782 | Dec 30, 2024 |
| Dec 16, 2024 | POpen-market purchase Common Stock10b5-1 | +10 | $2.21 | $22 | 29,792 | Dec 30, 2024 |
| Dec 17, 2024 | POpen-market purchase Common Stock10b5-1 | +10 | $2.12 | $21 | 29,802 | Dec 30, 2024 |
| Dec 18, 2024 | POpen-market purchase Common Stock10b5-1 | +10 | $2.19 | $22 | 29,812 | Dec 30, 2024 |
| Dec 19, 2024 | POpen-market purchase Common Stock10b5-1 | +4 | $2.33 | $9 | 29,816 | Dec 30, 2024 |
| Dec 20, 2024 | POpen-market purchase Common Stock10b5-1 | +2 | $2.35 | $5 | 29,818 | Dec 30, 2024 |
Related signals
Other insiders at CUMBERLAND PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 29Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $858 168 shares | +0% | |
| 19Weak | CUMBERLAND PHARMACEUTICALS INC | Caroline Young director | $429 84 shares | +0% | |
| 19Weak | CUMBERLAND PHARMACEUTICALS INC | James Jones director | $858 168 shares | +0% | |
| 19Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,824 945 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,635 1,035 shares | +0% | |
| 33Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $833 186 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | James Jones director | $833 186 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Caroline Young director | $417 93 shares | +0% | |
| 14Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,548 875 shares | +0% | |
| 24Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $881 168 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.